An orexin pill sharply improved wakefulness in narcolepsy type 1

Narcolepsy type 1 is caused by the loss of orexin, a brain chemical that keeps people awake, and the newest drugs for it try to put that signal back. A phase 2 trial in the Lancet Neurology reports that one such drug, the oral orexin 2 receptor agonist alixorexton, produced large improvements in wakefulness over six weeks — a striking early result that comes from a short, manufacturer-funded study [s1].

The mechanism

In narcolepsy type 1, the brain cells that make orexin (also called hypocretin) are destroyed, leaving patients with overwhelming daytime sleepiness and, often, cataplexy — sudden losses of muscle tone triggered by emotion [s1]. Rather than stimulating the nervous system broadly, as older drugs do, orexin 2 receptor agonists aim to replace the missing signal directly at its receptor [s1]. Alixorexton is one of several such compounds now in development, and the approach has already shown promise for both sleepiness and cataplexy in earlier work with this drug class [s1].

What they did

Vibrance-1 was a randomised, double-blind, placebo-controlled phase 2 trial, run at 46 hospitals and research centres across the USA, Europe and Australia [s1]. Adults aged 18 to 70 with narcolepsy type 1 — confirmed by overnight sleep study and a daytime nap test or by low cerebrospinal orexin — were centrally randomised 1:1:1:1 to 4 mg, 6 mg or 8 mg of alixorexton or to placebo, taken once daily for six weeks, followed by an optional seven-week open-label extension [s1]. Sponsor, assessors, investigators and participants were all masked during the double-blind period [s1]. The primary endpoint was the change from baseline to week 6 in mean sleep latency on the Maintenance of Wakefulness Test — a laboratory measure of how long a person can stay awake in quiet, sleep-inducing conditions, where a longer latency is better [s1].

What it showed

Of 153 people screened, 92 were randomly assigned: 23 to 4 mg, 22 to 6 mg, 24 to 8 mg and 23 to placebo [s1]. Their mean age was 33.5 years, and 57 (62%) were women [s1]. At week 6, the observed mean sleep latency was 2.3 minutes on placebo, against 24.0 minutes on 4 mg, 25.9 minutes on 6 mg and 28.2 minutes on 8 mg [s1]. In the formal analysis, the placebo-corrected least-squares mean improvement was 22.2 minutes (95% confidence interval, 17.2 to 27.2) for 4 mg, 24.1 minutes (19.0 to 29.1) for 6 mg and 26.0 minutes (21.0 to 31.0) for 8 mg, with adjusted p=0.0099 for the lowest dose and p<0.0001 for the two higher doses [s1]. On a test whose scale tops out around 40 minutes, moving from roughly two minutes to the mid-twenties is a large shift.

The side effects

The adverse events were largely what the drug's mechanism would predict — orexin's normal roles include promoting urination and wakefulness [s1]. Among participants given alixorexton, the events occurring in at least 5% and more often than on placebo were frequent urination (38, or 55%), insomnia (19, or 28%), excessive saliva (17, or 25%), urinary urgency (10, or 14%), blurred vision (10, or 14%) and excessive sweating (5, or 7%) [s1]. The trial describes the drug as generally well tolerated, with adverse events consistent with the known on-target effects of this drug class [s1].

How to read it

Three limits frame the enthusiasm. First, this is a phase 2 trial of 92 people over six weeks [s1]: it is sized and timed to justify a larger study, not to establish long-term efficacy or catch uncommon harms. Narcolepsy is lifelong, and how the drug performs — and how safely — over months and years is simply not addressed here. Second, the primary endpoint is a laboratory measure of staying awake; the trial reports benefits on daytime sleepiness and cataplexy too [s1], but a physiological test result is a step removed from how a patient functions across a real day. Third, and most plainly, the study was funded by Alkermes, the drug's manufacturer [s1] [s2] — a fact that does not invalidate a blinded, placebo-controlled result but is the standard reason to want independent, longer replication before drawing firm conclusions.

What to watch

The trial's own conclusion is that the findings support phase 3 evaluation [s1], and that is the right frame: alixorexton has cleared an early bar, not a final one. The larger trials will test whether the effect holds beyond six weeks, whether it translates into everyday functioning, and how the drug compares with the other orexin agonists racing through development for the same small group of patients.

Sources

• [s1] Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology. 24 August 2026.
• [s2] ClinicalTrials.gov. A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (Vibrance-1, NCT06358950). U.S. National Library of Medicine.